News
GRFS
7.28
-1.62%
-0.12
Grifols Reshapes Board and ESG Committee Following Director Resignation
TipRanks · 12h ago
Grifols names Ester Masllorens Llinàs to board as independent director after Felip Font resignation
PUBT · 12h ago
Weekly Report: what happened at GRFS last week (0615-0619)?
Weekly Report · 20h ago
Grifols Shareholders Approve 2025 Accounts and July Dividend, Renew Deloitte Mandate
TipRanks · 4d ago
Grifols shareholders approve up to 10% share capital cut via treasury share cancellations
PUBT · 4d ago
Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities
PUBT · 6d ago
Grifols announces U.S. launch of new fibrinogen concentrate
TipRanks · 06/15 12:50
GRIFOLS - ANNOUNCES U.S. LAUNCH OF NEW FIBRINOGEN CONCENTRATE
Reuters · 06/15 12:05
GRIFOLS - LAUNCHES NEW FIBRINOGEN CONCENTRATE FESILTY (FIBRINOGEN, HUMAN-CHMT) IN THE U.S.
Reuters · 06/15 12:01
GRIFOLS - FESILTY TO BE USED FOR ACUTE BLEEDING EPISODES IN PEDIATRIC AND ADULT PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Reuters · 06/15 12:01
Weekly Report: what happened at GRFS last week (0608-0612)?
Weekly Report · 06/15 10:34
Grifols to invest EUR 180 million in Egypt plasma-derivatives expansion through 2029
PUBT · 06/12 09:24
Weekly Report: what happened at GRFS last week (0601-0605)?
Weekly Report · 06/08 10:29
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Seeking Alpha · 06/04 11:18
Grifols breaks ground on EUR 160 million plasma plant in Spain
PUBT · 06/03 11:31
Weekly Report: what happened at GRFS last week (0525-0529)?
Weekly Report · 06/01 10:35
Weekly Report: what happened at GRFS last week (0518-0522)?
Weekly Report · 05/25 10:38
Aviva’s Probitas Canada integrates Volante Canada underwriting team into Toronto unit
PUBT · 05/21 15:05
PRESS DIGEST-Canada - May 18
Reuters · 05/18 12:04
Weekly Report: what happened at GRFS last week (0511-0515)?
Weekly Report · 05/18 10:38
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.